Stock Analiz

PolyPid Ltd. PYPD

Medical/Dental Instruments · IPO 2020 · data as of November 13, 2026

$6.26Market cap $127M
Open the interactive analysis →

PolyPid Ltd. (PYPD) is a healthcare company listed in the US with a market value of about $127M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -137%.

About PolyPid

PolyPid is listed in the US and classified in medical/dental instruments, IPO year 2020. It was profitable in 1 of the last 8 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B23.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-22.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)-56.5%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-137.0%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 8 years

Fiscal year20252024202320222021202020192018
Revenue————————
Net income-$34M-$29M-$24M-$40M-$43M-$37M-$7M$6M
Free cash flow-$28M-$22M-$17M-$36M-$35M-$22M-$18M-$20M
EPS (diluted)$-1.68$-1.43$-1.17$-1.95$-2.10$-1.82$-0.34$0.29
Net margin————————
ROIC-128.9%-128.0%-186.6%-146.6%-94.8%-28.5%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $11.50, 84% above the current price; targets range from $8.50 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-0.98 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does PolyPid pay a dividend?

Not currently.

Is PolyPid a good stock to buy?

We do not give buy or sell advice. PolyPid scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.